SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CNSI Cambridge Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Hansy who wrote (239)9/17/1997 12:16:00 PM
From: Ahda   of 675
 
,

CAMBRIDGE, Mass. -(Dow Jones)- Shares of Cambridge NeuroScience
Inc. plunged Tuesday after the biotech firm said it discontinued
a late-phase trial of its lead product, Cerestat, as a
brain-injury treatment because it didn't prove that it would
work well enough.

Cambridge said that in the brain-injury trial, there appeared
to be no difference between patients receiving Cerestat and
patients getting a placebo. That suggested that continuation of
the phase III study would be "unlikely to lead to a
statistically significant outcome," the company said.

Cerestat was the company's main potential product. In June,
analysts pointed out that the other drugs Cambridge NeuroScience
has in development are still in very early preclinical tests.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News